Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene variations are linked to the development of numerous cancers, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC). The lack of typical drug-binding sites has long hampered the discovery of therapeutic drugs targeting KRAS. Since “CodeBreaK 100” demonstrated Sotorasib’s early safety and efficacy and led to its approval, especially in the treatment of non-small cell lung cancer (NSCLC), the subsequent identification of specific inhibitors for the p.G12C mutation has offered hope. However, the CodeBreaK 200 study found no significant difference in overall survival (OS) between patients treated with Docetaxel and Sotorasib (AMG 510), adding another degree of complexity to this ongoing challenge. The current study compares the three-dimensional structures of the two major KRAS isoforms, KRAS4A and KRAS4B. It also investigates the probable structural changes caused by the three major mutations (p.G12C, p.G12D, and p.G12V) within Sotorasib’s pocket domain. The computational analysis demonstrates that the wild-type and mutant isoforms have distinct aggregation propensities, resulting in the creation of alternate oligomeric configurations. This study highlights the increased complexity of the biological issue of using KRAS as a therapeutic target. The present study stresses the need for a better understanding of the structural dynamics of KRAS and its mutations to design more effective therapeutic approaches. It also emphasizes the potential of computational approaches to shed light on the complicated molecular pathways that drive KRAS-mediated oncogenesis. This study adds to the ongoing efforts to address the therapeutic hurdles presented by KRAS in cancer treatment.
Kirsten大鼠肉瘤病毒癌基因同源物（KRAS）基因变异与多种癌症的发生发展密切相关，包括非小细胞肺癌（NSCLC）、结直肠癌（CRC）和胰腺导管腺癌（PDAC）。长期以来，由于缺乏典型的药物结合位点，针对KRAS的治疗药物研发进展缓慢。自“CodeBreaK 100”研究证实Sotorasib的早期安全性和有效性并推动其获批（尤其在非小细胞肺癌治疗领域）以来，针对p.G12C突变特异性抑制剂的发现为这一领域带来了希望。然而，CodeBreaK 200研究发现多西他赛与Sotorasib（AMG 510）治疗患者的总生存期（OS）无显著差异，这为当前面临的挑战增添了新的复杂性。 本研究比较了KRAS两种主要亚型（KRAS4A与KRAS4B）的三维结构，并探究了Sotorasib结合口袋区域内三种主要突变（p.G12C、p.G12D和p.G12V）可能引发的结构变化。计算分析表明，野生型与突变型亚型具有不同的聚集倾向，从而导致形成不同的寡聚构型。这一发现凸显了以KRAS为治疗靶点所涉及的生物学问题的复杂性。 本研究强调，需要更深入地理解KRAS及其突变的结构动力学特性，以设计更有效的治疗策略。同时，研究也揭示了计算方法在阐明驱动KRAS介导的肿瘤发生的复杂分子通路方面的潜力。本研究成果为持续攻克KRAS在癌症治疗中带来的治疗难题提供了新的科学依据。
The Target Therapy Hyperbole: “KRAS (p.G12C)”—The Simplification of a Complex Biological Problem
肿瘤(癌症)患者之家